

Date 22/05/2025  
Your Ref  
Our Ref 10053

Enquiries to Richard Mutch  
Extension 35687  
Direct Line 0131 465 5687  
[loth.freedomofinformation@nhs.scot](mailto:loth.freedomofinformation@nhs.scot)  
[richard.mutch@nhs.scot](mailto:richard.mutch@nhs.scot)

Dear

## FREEDOM OF INFORMATION - DERMATOLOGY PRESCRIBING

I write in response to your request for information in relation to Dermatology prescribing.

### Question:

- How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:
  - Adalimumab - Humira
  - Adalimumab Biosimilar
  - Apremilast
  - Bimekizumab
  - Brodalumab
  - Certolizumab
  - Deucravacitinib
  - Dimethyl fumarate
  - Etanercept - Enbrel
  - Etanercept Biosimilar
  - Guselkumab
  - Infliximab - Remicade
  - Infliximab Biosimilar
  - Ixekizumab
  - Risankizumab
  - Secukinumab
  - Tildrakizumab
  - Ustekinumab - Stelara
  - Ustekinumab Biosimilar
  - Spesolimab

Headquarters  
Mainpoint  
102 West Port  
Edinburgh EH3 9DN

**Chair Professor John Connaghan CBE**  
**Chief Executive Professor Caroline Hiscox**  
*Lothian NHS Board is the common  
name of Lothian Health Board*

Answer:

| February 2025 - April 2025 |               |
|----------------------------|---------------|
| Medication                 | Patient Count |
| Adalimumab - Humira        | 5<            |
| Adalimumab Biosimilar      | 299           |
| Apremilast                 | 15            |
| Bimekizumab                | 5<            |
| Brodalumab                 | 0             |
| Certolizumab               | 5<            |
| Deucravacitinib            | 0             |
| Dimethyl fumarate          | 5<            |
| Etanercept - Enbrel        | 5<            |
| Etanercept Biosimilar      | 11            |
| Guselkumab                 | 75            |
| Infliximab - Remicade      | 0             |
| Infliximab Biosimilar      | 5<            |
| Ixekizumab                 | 13            |
| Risankizumab               | 81            |
| Secukinumab                | 28            |
| Tildrakizumab              | 5<            |
| Ustekinumab - Stelara      | 5<            |
| Ustekinumab Biosimilar     | 56            |
| Spesolimab                 | 0             |

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the table above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at [www.itspublicknowledge.info/Appeal](http://www.itspublicknowledge.info/Appeal). If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI/Pages/default.aspx>

Yours sincerely

**ALISON MACDONALD**  
**Executive Director, Nursing**  
Cc: Chief Executive